ReviewCritical reviews in biomedical engineering2010
Molecular networks in drug discovery.
Review in Critical reviews in biomedical engineering, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The Immunosuppressive Properties of Cyclo-[Pharmaceutics · 2024Article
- Consolidation of network and experimental pharmacology to divulge the antidiabetic action of3 Biotech · 2021Article
- Repositioned Drugs for Inflammatory Diseases such as Sepsis, Asthma, and Atopic Dermatitis.Biomolecules & therapeutics · 2020Review
- Medicinal Effect,Scientifica · 2020Review
- Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice.Alcoholism, clinical and experimental research · 2020Review
- Novel Treatment Targets Based on Insights in the Etiology of Depression: Role of IL-6 Trans-Signaling and Stress-Induced Elevation of Glutamate and ATP.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Quantification of network structural dissimilarities.Nature communications · 2017Article
- Study of apoptosis-related interactions in colorectal cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.Schizophrenia research and treatment · 2016Review
- Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders.Annual review of pharmacology and toxicology · 2016Review
- Curation and analysis of multitargeting agents for polypharmacological modeling.Journal of chemical information and modeling · 2014Article
- System-level multi-target drug discovery from natural products with applications to cardiovascular diseases.Molecular diversity · 2014Article
- Miniature short hairpin RNA screens to characterize antiproliferative drugs.G3 (Bethesda, Md.) · 2013Article
- A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2013Article
- Visual data mining of biological networks: one size does not fit all.PLoS computational biology · 2013Article
- Polypharmacology: drug discovery for the future.Expert review of clinical pharmacology · 2013Review
- Predicting new molecular targets for rhein using network pharmacology.BMC systems biology · 2012Article
- The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells.Molecular cancer research : MCR · 2012Article
- From laptop to benchtop to bedside: structure-based drug design on protein targets.Current pharmaceutical design · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite the dramatic increase of global spending on drug discovery and development, the approval rate for new drugs is declining, due chiefly to toxicity and undesirable side effects. Simultaneously, the growth of available biomedical data in the postgenomic era has provided fresh insight into the nature of redundant and compensatory drug-target pathways. This stagnation in drug approval can be overcome by the novel concept of polypharmacology, which is built on the fundamental concept that drugs modulate multiple targets. Polypharmacology can be studied with molecular networks that integrate multidisciplinary concepts including cheminformatics, bioinformatics, and systems biology. In silico techniques such as structure- and ligand-based approaches can be employed to study molecular networks and reduce costs by predicting adverse drug reactions and toxicity in the early stage of drug development. By amalgamating strides in this informatics-driven era, designing polypharmacological drugs with molecular network technology exemplifies the next generation of therapeutics with less of-target properties and toxicity. In this review, we will first describe the challenges in drug discovery, and showcase successes using multitarget drugs toward diseases such as cancer and mood disorders. We will then focus on recent development of in silico polypharmacology predictions. Finally, our technologies in molecular network analysis will be presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.